Here are the 10-K annual reports from Eikon Therapeutics, Inc. (EIKN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow EIKN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EIKN filings page.
Eikon Therapeutics is a late-stage clinical biopharmaceutical company focused on oncology, advancing multiple candidates including EIK1001, EIK1003, EIK1004, EIK1005 and EIK1006. The company reported a 2025 net loss of $324.2 million, driven mainly by research and development spending of $250.3 million and general and administrative costs of $88.6 million.
Cash, cash equivalents and marketable securities totaled $336.0 million at year-end, and a February 2026 IPO added about $349.0 million of net proceeds, which management expects to fund operations into the second half of 2027. Eikon highlights a material weakness in internal control over financial reporting and notes a prior restatement of 2025 interim financials, as well as substantial future funding needs typical for a clinical-stage biotech with an accumulated deficit of $920.5 million.